Starting patients on the V-Go Disposable Insulin Delivery Device A simple guide for your practice For adult patients with Type 2 diabetes on basal insulin who need to take the next step
Identify appropriate candidates Add prandial control with V-Go Ideal patients to start on V-Go Elevated A1C (A1C 8%) 1 Basal insulin dose 30 U/day or 0.5 U/kg 2,3 After 12 weeks of basal insulin titration 4-6 Patients who may not be appropriate for V-Go Patients who have to make regular adjustments or modifications to their basal rate during a 24-hour period, or whose amount of insulin used at meals requires adjustments of less than 2-Unit increments, should not use V-Go as it may result in hypoglycemia. See the V-Go Instructions for Patient Use (Section 3) for the Indication, Warnings, and other safety information for V-Go. 2
Start V-Go: 3 easy steps 1. Write prescriptions for V-Go and insulin* 2. Ensure patients know how to use V-Go 3. Direct patients to call Valeritas Customer Care (VCC) * A U-100 fast-acting insulin should be used with V-Go. Humalog (insulin lispro, rdna origin) and NovoLog (insulin aspart, rdna origin) have been tested by Valeritas, Inc. and found to be safe for use in V-Go. Humalog is a registered trademark of Eli Lilly and Company. NovoLog is a registered trademark of Novo Nordisk A/S.
Meet patient needs with 3 V-Go options * * * *You can only click the Bolus Delivery Button 18 times in every 24-hour period. Each click of the Bolus Delivery Button delivers 2 Units of insulin (1 click = 2 Units). A co-pay reduction card is available for commercially insured patients. Download it at www.go-vgo.com/co-pay-card. 4
Get patients started with 2 prescriptions V-Go Select the appropriate V-Go option Rx: Size: Package size: Sig: Disp: #30 Dosage form: Device V-Go 20 U, 30 U, 40 U Each Use 1 V-Go for 24 hours as directed NDC: V-Go 20: 08560-9400-03 V-Go 30: 08560-9400-02 V-Go 40: 08560-9400-01 Insulin U-100 fast-acting insulin* 2 vials for V-Go 20 3 vials for V-Go 30 and V-Go 40 Click on Humalog or NovoLog Click unstructured and type in the Sig, Disp, and Pharmacy notes Example: For V-Go 30 insulin erx Sig: Disp: Pharmacy notes: Inject subcutaneous daily. #3 x 10 ml vials required per month for use in V-Go 30. Total daily dose will vary. Per FDA labeling, V-Go 30 requires 3 vials of insulin per month. * A U-100 fast-acting insulin should be used with V-Go. Humalog (insulin lispro, rdna origin) and NovoLog (insulin aspart, rdna origin) have been tested by Valeritas, Inc. and found to be safe for use in V-Go. Humalog is a registered trademark of Eli Lilly and Company. NovoLog is a registered trademark of Novo Nordisk A/S.
V-Go dosing Initiate Goal: Reach 50/50 split on the daily basal-bolus insulin dose 3,7 Adults on basal insulin only (± OADs) 3,8 Patient s body weight 220 lb >220 lb x 0.45 kg/lb x 0.5 U/kg Basal rate V-Go 20 Units/24 hours Basal rate V-Go 30 Units/24 hours Bolus dosing 2 clicks/meal 1 click = 2 Units Bolus dosing 3 clicks/meal 1 click = 2 Units When appropriate, consider advising patients to click when they snack. Ensure that your patients have a plan to manage hypoglycemia and hyperglycemia. 6
V-Go dosing Titrate Goal: Reach 50/50 split on the daily basal-bolus insulin dose 3,7 Improving postprandial glucose can help reduce fasting and preprandial glucose levels and improve control. 9-13 As with any insulin therapy: Titration with V-Go is critical to improving glycemic control. First optimize bolus Adjust basal if needed If mealtime blood glucose is consistently not at goal, add clicks weekly until optimized After optimizing bolus dosing, increase the V-Go option if A1C is not at goal or fasting glucose is still elevated
Make sure patients know how to use V-Go Easy to fill Patients fill a new V-Go with insulin each day. Easy to apply Patients simply place V-Go on their skin and press the Needle Button to start the basal rate. Easy to use Patients use the Bolus Ready Button and Bolus Delivery Button at mealtimes. (1 click = 2 Units) For the simple steps on how to fill, apply, and use V-Go, refer to the print, interactive, or video versions of the Quick Reference Guide at www.go-vgo.com. Ensure that patients understand basal-bolus therapy and that they have a plan to manage hypoglycemia and hyperglycemia. 8
Direct patients to enroll in Valeritas Customer Care (VCC) Comprehensive benefits for you and your patients, including a 1:1 partnership with a dedicated representative and 24/7 support at 1-866-881-1209. Benefits for your patients Benefits for you Responds to V-Go questions live anytime 24/7 assistance Decreases call frequency to your office and offers patient support after hours Provides expert personalized insurance guidance and benefits investigation Reimbursement help Fewer phone calls and contacts with insurance companies Makes obtaining V-Go and using the co-pay card easy Pharmacy support Patients easily get the product you prescribe for them Provides initial instruction plus follow-up to help patients succeed with V-Go V-Go use Lessens staff time needed to show patients how to fill, apply, and use V-Go Keep your patients on track with regular calls over the first 90 days Follow-up calls Promote patient compliance while reducing the need for office follow-up Provides online access to practical information about diabetes and V-Go V-Go Life TM Self-Management Program Helps keep patients motivated and encourages compliance Valeritas does not give medical advice about insulin therapy. Patients should discuss all medical therapies with you and follow your instructions.
Take the next step V-Go delivers a continuous preset basal rate of insulin plus on-demand bolus dosing at mealtimes, which may help improve glycemic control. 9,14-16 10
Notes
3 easy steps to starting your patients on V-Go 1. Write prescriptions for V-Go and insulin* 2. Ensure patients know how to use V-Go 3. Direct patients to call Valeritas Customer Care (VCC) We re here 24/7 You and your patients can find help day or night. Call 1-866-881-1209 or visit www.go-vgo.com. Important Risk Information: If regular adjustments or modifications to the basal rate of insulin are required in a 24-hour period, or if the amount of insulin used at meals requires adjustments of less than 2-Unit increments, use of the V-Go Disposable Insulin Delivery Device may result in hypoglycemia. The following conditions may occur during insulin therapy with V-Go: hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose). Other adverse reactions associated with V-Go use include skin irritation from the adhesive pad or infections at the infusion site. V-Go should be removed before any magnetic resonance imaging (MRI) testing. *A U-100 fast-acting insulin should be used with V-Go. Humalog (insulin lispro, rdna origin) and NovoLog (insulin aspart, rdna origin) have been tested by Valeritas, Inc. and found to be safe for use in V-Go. References: 1. Nathan DM, et al. Diabetes Care. 2009;32(1):193-203. 2. Inzucchi SE, et al. Diabetes Care. 2012;35(6):1364-1379. 3. Edelman SV, et al. Diabetes Technol Ther. 2010;12(8):627-633. 4. Strange P. J Diabetes Sci Technol. 2007;1(4):540-548. 5. Riddle MC, et al. Diabetes Care. 2003;26(11):3080-3086. 6. In the treat-to-target study. http://www.lantus.com/hcp/about-lantus/vs-nph-efficacy. Accessed September 24, 2014. 7. Bode BW, et al. Diabetes Metab Res Rev. 2002;18(suppl 1):S14-S20. 8. Data on file. Valeritas, Inc. 9. Kapitza C, et al. J Diabetes Sci Technol. 2008;2(1):40-46. 10. Holman RR, et al. N Engl J Med. 2007;357(17):1716-1730. 11. Holman RR, et al. N Engl J Med. 2009;361(18):1736-1747. 12. Woerle HJ, et al. Diabetes Res Clin Pract. 2007;77(2):280-285. 13. Riddle M, et al. Diabetes Care. 2011;34(12):2508-2514. 14. Grunberger G, et al. Poster presented at: American Association of Clinical Endocrinologists 23rd Annual Scientific and Clinical Congress; May 14-18, 2014; Las Vegas, NV. Abstract 224. 15. Rosenfeld CR, et al. Endocr Pract. 2012;18(5):660-667. 16. Omer A, et al. Poster presented at: American Diabetes Association 73rd Scientific Sessions; June 21-25, 2013; Chicago, IL. Abstract 980-P. V-Go is a registered trademark of Valeritas, Inc. 12 ART-712 Rev: A 09/2014 2014 Valeritas, Inc.